SCHEMBL22200722

SCHEMBL22200722

CC(C)n1c(=O)c(-c2ccc(NS(=O)(=O)CCC(F)(F)F)c(F)c2)cc2cnc(NC3CCC(NC(=O)OC(C)(C)C)C(F)C3)nc21

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 6/20 0.52
BRAF P15056 2/20 0.39
MAPK8 P45983 7/20 0.36
MAPK10 P53779 6/20 0.36
MAPK9 P45984 5/20 0.36
SYK P43405 1/20 0.34
JAK1 P23458 1/20 0.34
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
CCNT1 O60563 1/20 0.33
CDK4 P11802 1/20 0.33
CCND1 P24385 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
CDK9 P50750 1/20 0.33
CDK6 Q00534 1/20 0.33
TRPV1 Q8NER1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29356090 1.00 ERN1 (0.52) ERN1BRAFMAPK8MAPK10MAPK9
SCHEMBL22190949 0.92 ERN1 (0.53) ERN1BRAFMAPK8MAPK10MAPK9
SCHEMBL25035621 0.90 ERN1 (0.55) ERN1BRAFMAPK8MAPK10MAPK9
SCHEMBL22200724 0.89 ERN1 (0.46) ERN1MAPK8MAPK10MAPK9SYK
SCHEMBL22200760 0.87 ERN1 (0.51) ERN1BRAFMAPK8MAPK10MAPK9
SCHEMBL22191326 0.87 ERN1 (0.51) ERN1BRAFMAPK8MAPK10MAPK9
SCHEMBL22200759 0.87 ERN1 (0.51) ERN1BRAFMAPK8MAPK10MAPK9
SCHEMBL22200754 0.87 ERN1 (0.55) ERN1BRAFMAPK8MAPK10MAPK9
SCHEMBL22200810 0.87 ERN1 (0.44) ERN1BRAFMAPK8MAPK10MAPK9
SCHEMBL29356354 0.87 ERN1 (0.44) ERN1BRAFMAPK8MAPK10MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed